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Editorial, see p 1948
BACKGROUND: Aortic valve replacement (AVR) for aortic stenosis is timed 
primarily on the development of symptoms, but late surgery can result in 
irreversible myocardial dysfunction and additional risk. The aim of this study was 
to determine whether the presence of focal myocardial scar preoperatively was 
associated with long-term mortality.
METHODS: In a longitudinal observational outcome study, survival analysis 
was performed in patients with severe aortic stenosis listed for valve 
intervention at 6 UK cardiothoracic centers. Patients underwent preprocedural 
echocardiography (for valve severity assessment) and cardiovascular magnetic 
resonance for ventricular volumes, function and scar quantification between 
January 2003 and May 2015. Myocardial scar was categorized into 3 patterns 
(none, infarct, or noninfarct patterns) and quantified with the full width at half-
maximum method as percentage of the left ventricle. All-cause mortality and 
cardiovascular mortality were tracked for a minimum of 2 years.
RESULTS: Six hundred seventy-four patients with severe aortic stenosis 
(age, 75±14 years; 63% male; aortic valve area, 0.38±0.14 cm2/m2; mean 
gradient, 46±18 mm Hg; left ventricular ejection fraction, 61.0±16.7%) were 
included. Scar was present in 51% (18% infarct pattern, 33% noninfarct). 
Management was surgical AVR (n=399) or transcatheter AVR (n=275). 
During follow-up (median, 3.6 years), 145 patients (21.5%) died (52 after 
surgical AVR, 93 after transcatheter AVR). In multivariable analysis, the factors 
independently associated with all-cause mortality were age (hazard ratio [HR], 
1.50; 95% CI, 1.11–2.04; P=0.009, scaled by epochs of 10 years), Society 
of Thoracic Surgeons score (HR, 1.12; 95% CI, 1.03–1.22; P=0.007), and 
scar presence (HR, 2.39; 95% CI, 1.40–4.05; P=0.001). Scar independently 
predicted all-cause (26.4% versus 12.9%; P<0.001) and cardiovascular 
(15.0% versus 4.8%; P<0.001) mortality, regardless of intervention 
(transcatheter AVR, P=0.002; surgical AVR, P=0.026 [all-cause mortality]). 
Every 1% increase in left ventricular myocardial scar burden was associated 
with 11% higher all-cause mortality hazard (HR, 1.11; 95% CI, 1.05–1.17; 
P<0.001) and 8% higher cardiovascular mortality hazard (HR, 1.08; 95% CI, 
1.01–1.17; P<0.001).
CONCLUSIONS: In patients with severe aortic stenosis, late gadolinium 
enhancement on cardiovascular magnetic resonance was independently 
associated with mortality; its presence was associated with a 2-fold higher late 
mortality.
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Aortic stenosis (AS) is the most common valvular heart disease.1 It is characterized by progressive narrowing of the aortic valve and by hypertro-
phic remodeling of the left ventricular (LV) myocar-
dium.2 This process maintains wall stress and cardiac 
performance for many years, but ultimately the LV de-
compensates, heralding the transition to heart failure, 
symptom development, and death.3 The treatment for 
AS is valve replacement, with the goal of reducing both 
symptoms and mortality.
Current guidelines recommend aortic valve inter-
vention by surgical aortic valve replacement (SAVR) or 
transcatheter aortic valve replacement (TAVR) in symp-
tomatic severe AS or for asymptomatic severe AS in the 
presence of LV dysfunction or exercise-invoked symp-
toms.4 However, symptoms can be difficult to interpret, 
especially in the elderly, who may be less active or have 
multiple comorbidities, and reduction in ejection frac-
tion is often irreversible and associated with increased 
risk of heart failure and death.5
Although the primary insult is valve stenosis, the car-
diac response to this may be equally important. There-
fore, there is growing interest in objective and early 
markers of cardiac decompensation. Histological and 
imaging studies have suggested that focal myocardial 
fibrosis is a key driver in the transition from hypertro-
phy to heart failure.6–10 Myocardial replacement fibrosis 
(scar) can be detected by cardiovascular magnetic reso-
nance (CMR) with the late gadolinium enhancement 
(LGE) technique. From single-center studies, focal fibro-
sis has been associated with increased levels of myocar-
dial injury, diastolic and systolic dysfunction, electrocar-
diographic changes, and adverse clinical outcomes.7–10 
Focal scar by LGE is irreversible at 9 and 12 months 
after SAVR.5,11 CMR-detected myocardial fibrosis there-
fore appears to be a useful and objective biomarker of 
LV decompensation in AS.
Prior studies have been too small to evaluate the 
independent association of imaging biomarkers and 
demographic factors with total and cardiovascular mor-
tality in patients with severe AS.7–10 We established a 
UK consortium to determine which preoperative factors 
were most strongly associated with long-term postop-
erative mortality in patients with severe AS on conven-
tional management pathways, which could potentially 
be used to time surgery better in the future. We hy-
pothesized that myocardial scarring detected by LGE-
CMR would be independently associated with mortal-
ity in patients with severe AS undergoing aortic valve 
intervention.
METHODS
The data, analytical methods, and study materials will be 
made available to other researchers for purposes of reproduc-
ing the results or replicating the procedure. The data are avail-
able from the corresponding author on reasonable request.
Patients and Study Design
A longitudinal, observational outcome study in patients with 
severe AS referred to 6 UK cardiothoracic surgical centers and 
listed for valve intervention (Brompton Hospital and Barts 
Heart Center in London; Edinburgh Heart Center; Glenfield 
Hospital in Leicester; Leeds Teaching Hospitals National Health 
Service Trust; John Radcliffe Hospital in Oxford). Between 
January 2003 and May 2015, patients were prospectively 
recruited after evaluation by the multidisciplinary heart team. 
The study was approved by the UK National Research Ethics 
Service (13/NW/0832) and conformed to the principles of the 
Declaration of Helsinki, and all patients gave written informed 
consent. The primary end point was all-cause mortality. The 
secondary end point was cardiovascular disease–related mor-
tality as defined by diagnosis on the UK death certificate. 
Patients >18 years of age with severe AS (1 of the following: 
aortic valve area <1 cm2, peak pressure gradient >64 mm Hg, 
mean pressure gradient >40 mm Hg, or peak velocity >4 m/s) 
who had undergone CMR imaging for research purposes 
were included.
Image Acquisition
Echocardiographic parameters were acquired as part of the 
clinical workup following the guidelines for assessment of AS 
severity recommended by the American and European soci-
eties of echocardiography.12 Global hemodynamic load was 
measured by calculating the valvulo-arterial impedance index, 
defined as the ratio of the estimated LV systolic pressure (sum 
of systolic arterial pressure and mean pressure gradient) to 
the stroke volume indexed for body surface area. CMR was 
performed on 1.5- and 3-T scanners using standardized 
Clinical Perspective
What Is New?
• In patients with severe aortic stenosis, focal myo-
cardial fibrosis (scar) determined by cardiovascu-
lar magnetic resonance was present in >50% of 
patients and was associated with a 2-fold higher 
late mortality.
• Focal scar (both infarct and noninfarct patterns) 
was independently associated with all-cause and 
cardiovascular mortality after both surgical and 
transcatheter aortic valve replacement.
What Are the Clinical Implications?
• In severe aortic stenosis, late gadolinium enhance-
ment appears to be a useful biomarker of left ven-
tricular remodeling, and its presence is associated 
with worse long-term outcomes after aortic valve 
intervention.
• This raises the hypothesis that, for some patients, 
timing of aortic valve intervention may be too late 
once scar has developed and that randomized trials 
of earlier intervention are now required.
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protocols. In brief, cine images were acquired in long-axis 
planes and contiguous short-axis slices for ventricular vol-
umes, mass, and function. Phase-contrast velocity-encoded 
images were acquired for valve hemodynamics, and the LGE 
technique was used to identify myocardial scar, as previously 
described.13 All participating centers have previously pub-
lished single-center mechanistic data in AS in which image 
quality and specific CMR pulse sequence parameters can be 
reviewed.10,14–17
Data Management and Outcomes
Anonymized clinical and imaging data were collected and 
managed with REDCap (Research Electronic Data Capture) 
software18 hosted at Barts Heart Center/University College 
London. All deaths were identified through the UK National 
Health Service National Spine Database. Cardiovascular mor-
tality was established in all deceased individuals from the offi-
cial death certificates, which in the United Kingdom list up 
to 3 causes of death and were adjudicated by 2 readers (P.B., 
J.P.G.) blinded to all clinical data. Cardiovascular mortality 
was defined as death attributable to myocardial ischemia and 
infarction, heart failure, cardiac arrest resulting from arrhyth-
mia or unknown cause, or cerebrovascular accident.
Data Analysis
All CMR scans were centralized and rereported in core lab-
oratory fashion by experienced readers blinded to clinical 
parameters using CVI42 software (Circle Calgary). Each cen-
ter analyzed a single component of the CMR scan for the 
entire study population, according to a prespecified standard 
operating procedure (online-only Data Supplement) and after 
a period of training and reproducibility evaluation. LV volume 
and mass analysis was performed by manual contouring of 
the endocardial and epicardial borders at end diastole and 
end systole.19 Left atrial area and length at end systole were 
measured in the horizontal (4-chamber) and vertical long-axis 
(2-chamber) views for calculation of left atrial volumes by the 
biplane area length method and indexed.19 Aortic flow for 
regurgitant volume and fraction was quantified from phase-
contrast velocity-encoded images.20 LGE was categorized by 
2 observers into 3 patterns (none, infarct, or noninfarct pat-
terns) and quantified with the full width at half-maximum 
method as percentage of the LV.13 Examples of typical echo-
cardiographic and CMR images are shown in Figure 1. Further 
technical details of the image analysis can be found in the 
online-only Data Supplement.
Statistics
Statistical analysis was performed in R (version 3.0.1; The 
R Foundation for Statistical Computing). Distribution of 
data was assessed on histograms and with the Shapiro-
Wilk test. Continuous variables are expressed as mean±SD 
or as median and interquartile range; categorical variables, 
as counts and percent. Baseline characteristics of partici-
pants were compared with the unpaired Student t test, 
Mann-Whitney-Wilcoxon test, χ2 test, or Fisher exact test as 
appropriate. The primary end point was all-cause mortality. 
The secondary end point was cardiovascular disease–related 
mortality. In addition, we computed early postintervention 
(TAVR/SAVR) mortality (defined as 30-day or in-hospital 
mortality). Survival in patients with and without LGE was 
evaluated with the Kaplan-Meier method and compared 
among groups with the log-rank test. The index date was 
the date of CMR. Hazard ratios (HRs) were expressed as 
mean±95% CIs.
All clinical parameters were proposed for inclusion in a 
univariate Cox proportional hazards model. The most predic-
tive candidate variable was selected from each of 3 domains 
if applicable (clinical, echocardiography, CMR) to avoid colin-
earity and then entered into the final model. Unique, clinically 
relevant predictor variables with a value of P<0.10 in univari-
ate analysis were entered into final multivariable models; a 
forward stepwise procedure was used. The incremental value 
between steps was measured by the χ2 method. The propor-
tional hazards assumption was tested with the use of log-log 
plots and examination of Schoenfeld residuals. All tests were 
2-sided; values of P<0.05 were considered significant.
Role of the Funding Source
No additional funding was obtained for this consortium study 
beyond that of the original single-center research funding. 
Funders provided financial support for the original data col-
lection but had no role in the consortium study design, data 
collection, data analysis, data interpretation, or writing of the 
report. All authors had access to the primary data and have 
final responsibility for publication.
RESULTS
Baseline Characteristics
Baseline characteristics of the 674 patients included 
are shown in Table  1 and Figure I in the online-only 
Data Supplement (study flowchart). Mean age was 
75±14 years (63% male) with a mean aortic valve area 
of 0.38±0.14 cm2/m2 and mean gradient of 46±18 
mm Hg. Median aortic valve regurgitant fraction was 
8.0% (interquartile range, 2.7%–17.3%); 16% of pa-
tients had at least moderately elevated pulmonary arte-
rial systolic pressure (defined as 30–55 mm Hg by echo-
cardiography). LV myocardial scar, as assessed by LGE, 
was present in 51% of patients in a 2:1 ratio between 
noninfarct (33%) and infarct (18%) pattern scar.
Management by Surgical Replacement 
Versus Transcatheter Replacement
Management was SAVR (n=399) or TAVR (n=275). 
Median time from CMR to SAVR was 44 days (in-
terquartile range, 11–103 days) and to TAVR was 
13 days (interquartile range, 1–61 days). Compared 
with SAVR, patients managed with TAVR were old-
er (79.2±7.8 versus 68.6±10.3 years; P<0.001) and 
more likely female (48% versus 29%; P<0.001) with 
more atrial fibrillation (21.1% versus 6.5%; P<0.001), 
more coronary artery disease (39.3% versus 19.5%; 
P<0.001), less hypertension (42.6% versus 59.5%; 
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P<0.001), and fewer bicuspid aortic valves (5.5% ver-
sus 33.8%; P<0.001). Patients undergoing TAVR had 
higher peak aortic valve gradients and smaller aortic 
valve area. Furthermore, patients undergoing TAVR 
had larger LV volumes and lower LV ejection fraction 
and had more severe symptoms; LV mass and LGE 
prevalence were not different between groups, al-
though infarct pattern scar was more prevalent in the 
TAVR group and noninfarct scar was more prevalent 
in the SAVR group.
Patient Characteristics According  
to LGE Status
LGE positive patients were more likely to be male (72.7 
versus 54.4%; P<0.001) and to have had a previous 
myocardial infarct (17.0% versus 4.0%; P<0.001) and 
had larger indexed LV end-diastolic volume, higher 
indexed LV mass, and lower LV ejection fraction (all 
P<0.001) than LGE negative patients (Table 1). In the 
SAVR cohort only, men also had higher New York Heart 
Association functional class (P=0.006) and higher sys-
tolic blood pressure (138.5±20.5 versus 134.0±17.8 
mm Hg; P=0.036).
Outcome
During a median 3.6 years of follow-up (interquartile 
range, 2.6–5.9 years), 145 patients (21.5%) died (52 
after SAVR and 93 after TAVR). This equated to 52 
deaths per 1000 patient-years (27 and 104 for SAVR 
and TAVR groups, respectively). A cardiovascular cause 
of death was ascribed to 70 patients (10.4% of whole 
cohort; 19 after SAVR [4.8%], 51 after TAVR [18.5%]). 
At 30 days after the intervention, overall mortality was 
1.8% (n=12), with 1.3% (n=5) for SAVR and 2.5% 
(n=7) for TAVR. At 1 year, overall mortality was 6.2% 
(n=42), with 3.0% (n=12) for SAVR and 10.9% (n=30) 
for TAVR (Table I in the online-only Data Supplement).
Predictors of Outcome
Fifty-two variables were compared with outcome (in-
cluding demographic, comorbidities, therapies, Society 
of Thoracic Surgeons score, and imaging [echocardiog-
raphy/CMR] parameters). In univariate analysis (Table 2 
and Tables II and III in the online-only Data Supplement 
for all, SAVR, and TAVR, respectively), 28 of them were 
associated with outcome. In multivariable analysis (Ta-
ble 3 and Tables IV and V in the online-only Data Supple-
ment for all, SAVR, and TAVR, respectively), the factors 
Figure 1. Multimodality assessment of aortic stenosis (AS). 
Assessment of AS by transthoracic echocardiography (TTE; A–C) and cardiovascular magnetic resonance (D–F). A, Continuous Doppler trace across the aortic valve 
in the apical 5-chamber demonstrating hemodynamic parameters consistent with severe AS (peak velocity, 4.67 m/s; peak gradient, 87 mm Hg; mean gradient, 
51 mm Hg). B, Short-axis TTE image of a severely calcified aortic valve. C, Parasternal long-axis image demonstrating left ventricular hypertrophy (#) and a calcified 
aortic valve (*). D, Four-chamber balanced steady-state free precession cine image demonstrating left ventricular hypertrophy; white dotted line demonstrates the 
axis of acquisition of the short axis (E and F). E, Late gadolinium enhancement (LGE) image in a midventricular short axis showing transmural LGE of a full-thick-
ness myocardial infarct (arrow). F, LGE image in a midventricular short axis showing patchy nonischemia LGE in the mid inferolateral segment (arrow) and more 
subtle LGE in the inferoseptum and right ventricular insertion points.
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Table 1. Baseline Characteristics
Variable
All Patients*
(n=674)
+LGE
(n=341)†
−LGE
(n=272)† P Value
Age (IQR), y 74.6 (14.4) 74.3 (14.6) 75.0 (14.5) 0.44
Intervention
  SAVR, n (%)‡ 399 (59.2) 194 (56.9) 176 (64.7) 0.05
  TAVR, n (%) 275 (40.8) 147 (43.1) 96 (35.3)
Male, n (%) 425 (63.1) 248 (72.7) 148 (54.4) <0.001
BMI, kg/m2 27.6±5.1 27.8±5.1 27.3±4.8 0.20
Atrial fibrillation, n (%) 84 (12.5) 49 (14.4) 28 (10.3) 0.13
Diabetes mellitus, n (%) 146 (21.7) 77 (22.6) 58 (21.3) 0.71
Hypertension, n (%) 358 (53.1) 184 (54.0) 155 (57.0) 0.46
Systolic BP, mm Hg 135.0±20.4 133.4±20.3 137.3±20.2 0.03
Diastolic BP, mm Hg 72.7±12.2 72.2±11.8 74.0±11.8 0.10
Bicuspid aortic valve, n (%)§ 149 (22.1) 80 (23.5) 53 (19.4) 0.23
Known CAD, n (%) 197 (29.2) 123 (36.1) 74 (27.2) 0.16
No previous PCI/CABG, n (%)§ 533 (79.1) 260 (76.2) 220 (80.9) 0.65
Previous PCI, n (%) 57 (8.5) 38 (11.1) 16 (5.9) 0.07
Previous CABG, n (%) 58 (8.6) 31 (9.1) 22 (8.1) 0.92
History of MI, n (%)§ 73 (10.8) 58 (17.0) 11 (4.0) <0.001
STS Mortality Risk score (IQR), % 1.75 (1.89) 1.74 (1.79) 1.76 (1.69) 0.78
EuroSCORE II, % 1.81 (2.40) 1.87 (2.85) 1.64 (1.69) 0.07
NYHA functional class, n (%)§
  I 81 (12.0) 33 (9.7) 47 (17.3) 0.03
  II 258 (38.3) 138 (40.5) 90 (33.1)
  III 248 (36.8) 127 (37.2) 98 (36.0)
  IV 22 (3.3) 10 (2.9) 8 (2.9)
Baseline medications, n (%)§
  ACE inhibitor or ARB 262 (38.9) 139 (40.8) 107 (39.3) 0.56
  β-Blocker 240 (35.6) 130 (38.1) 92 (33.8) 0.27
  Aldosterone antagonist* 36 (5.3) 21 (61.6) 11 (4.0) 0.12
  Statin 406 (60.2) 224 (65.7) 162 (59.6) 0.23
Echocardiographic data
  Mean aortic valve gradient (IQR), mm Hg 46.0 (18.0) 46.0 (19.0) 46.0 (17.0) 0.20
  Peak aortic valve gradient (IQR), mm Hg 78.0 (30.0) 78.0 (30.0) 79.5 (30.0) 0.34
  AVA (IQR), cm2 0.70 (0.31) 0.70 (0.21) 0.70 (0.17) 0.98
  Indexed AVA (to BSA) (IQR), cm2/m2 0.38 (0.14) 0.41 (0.13) 0.40 (0.13) 0.94
  Estimated PASP, n (%)     
   Normal§ 316 (46.9) 159 (46.6) 138 (50.7) 0.85
   Moderate (31–55 mm Hg) 80 (11.9) 43 (12.6) 30 (11.0)
   Severe (>55 mm Hg) 30 (4.5) 16 (4.7) 11 (4.0)
CMR data
  LV end-diastolic volume index (IQR), mL/m2 79.5 (29.3) 85.4 (33.4) 73.3 (23.1) <0.001
  LV stroke volume index (IQR), mL/m2 46.2 (14.5) 46.0 (14.9) 45.8 (14.2) 0.80
  LV ejection fraction (IQR), % 61.0 (16.7) 58.0 (21.0) 64.0 (12.0) <0.001
  Maximal LV wall thickness (IQR), mm 14.0 (4.0) 14.0 (4.0) 13.0 (3.0) <0.001
  LV mass index (IQR), g/m2 81.0 (31.0) 87.1 (31.3) 74.9 (28.5) <0.001
  RV end-diastolic volume index (IQR), mL/m2 67.4 (22.2) 68.5 (22.5) 66.8 (19.8) 0.015
(Continued )
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independently associated with all-cause mortality were 
age (HR, 1.50; 95% CI, 1.11–2.04; P=0.009, scaled by 
epochs of 10 years), Society of Thoracic Surgeons score 
(HR, 1.12; 95% CI, 1.03–1.22; P=0.007), and scar pres-
ence (HR, 2.39; 95% CI, 1.40–4.05; P=0.001). The in-
cremental effect of adding age, Society of Thoracic Sur-
geons score, and LGE presence to the risk stratification 
model is demonstrated in Figure II in the online-only Data 
Supplement; global Wald χ2 is shown for separate Cox 
regression models predicting all-cause death. For car-
diovascular mortality, the factors independently associ-
ated with all-cause mortality were age (HR, 1.94; 95% 
CI, 1.44–2.60; P<0.0001, scaled by epochs of 10 years), 
female sex (HR, 2.17; 95% CI, 1.28–3.70; P<0.001), LGE 
presence (HR, 3.14; 95% CI, 1.65–5.99; P<0.001), and 
reduced LV ejection fraction (HR, 0.98; 95% CI, 0.96–
1.00; P=0.013). Pulmonary artery systolic pressure was 
not included in the main model because data were avail-
able in only 63.3% (SAVR, 82.7%; TAVR, 49.5%), but 
when included, the presence of severely elevated pulmo-
nary arterial systolic pressure (>55 mm Hg) was an inde-
pendent predictor of all-cause mortality (HR, 2.73; 95% 
CI, 1.21–6.17; P=0.016; Table VI in the online-only Data 
Supplement). Neither coronary artery disease nor previ-
ous coronary revascularization (percutaneous coronary 
intervention or coronary artery bypass graft surgery) was 
an independent predictor of mortality (Table VII in the 
online-only Data Supplement). Furthermore, no echo-
cardiographic or CMR markers of aortic valve stenosis 
severity were independently predictive of mortality.
Patients with myocardial scar had higher (double) all-
cause mortality (26.4% versus 12.9%; P<0.001) and 3 
times the cardiovascular mortality (15.0% versus 4.8%; 
P<0.001), regardless of valve intervention type (TAVR, 
P=0.002; SAVR, P=0.026; Figure 2) and scar type, with 
both infarct and noninfarct scar being associated with 
similarly adverse outcomes (P<0.001 for both; Fig-
ure  3)—for example, all-cause mortality, 25.2% non-
infarct pattern LGE, 28.6% infarct pattern, and 12.9% 
no LGE. Quantitatively, every 1% increase in LV myocar-
dial scar burden was associated with an 11% higher all-
cause mortality hazard (HR, 1.11; 95% CI, 1.05–1.17; 
P<0.001) and an 8% higher cardiovascular mortality 
hazard (HR, 1.08; 95% CI, 1.01–1.17; P<0.001; Table 
VIII in the online-only Data Supplement). There was no 
significant change in results when events within 30 
days of intervention were excluded or the index date 
was changed from time of CMR to time of intervention 
(Tables IX and X in the online-only Data Supplement).
DISCUSSION
In patients with severe AS, in terms of disease-based 
parameters, we have shown that myocardial fibrosis 
(scar) is independently associated with mortality. This 
was the case for all-cause and cardiovascular mortality, 
after both surgical and transcatheter intervention, and 
for both infarct and noninfarct scar patterns. Specifical-
ly, every 1% increase in scar burden increased mortality 
hazard by 11% and cardiovascular mortality hazard by 
8%. Given that most of this scar is AS-related and that 
scar was present in half of the patients, we postulate 
that, for many patients, AS surgery is potentially oc-
curring too late and leaving patients with residual risk.
  RV ejection fraction (IQR), % 65.0 (13.0) 63.8 (15.0) 65.0 (11.0) 0.026
  Indexed left atrial volume (IQR), mL/m2 52.8 (25.7) 53.3 (24.4) 51.4 (25.4) 0.19
  CMR aortic valve regurgitant fraction (IQR), % 8.0 (14.7) 8.9 (16.2) 7.7 (12.2) 0.12
  Valvulo-arterial impedance (IQR) 3.93 (1.4) 3.93 (1.3) 3.98 (1.5) 0.20
  LGE present, n (%) 341 (50.6) 341 (100) 0 NA
   Noninfarct pattern 222 (32.9) 222 (65.1) 0 NA
   Infarct pattern 119 (17.7) 119 (34.9) 0 NA
  LGE mass (IQR), % 0.53‖ (3.08) 2.72 (3.95) 0 NA
Normally distributed continuous variables are expressed as mean±SD; nonparametric continuous variables are expressed as median (IQR); and categorical variables 
are expressed as counts (percent).
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; AVA, aortic valve area; BMI, body mass index; BP, blood pressure; BSA, body 
surface area; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CMR, cardiovascular magnetic resonance; IQR, interquartile range; LGE, late 
gadolinium enhancement; LV, left ventricular; MI, myocardial infarction; NA, not available; NYHA, New York Heart Association; PASP, pulmonary artery systolic 
pressure; PCI, percutaneous coronary intervention; RV, right ventricular; SAVR, surgical aortic valve replacement; STS, Society of Thoracic Surgeons; and TAVR, 
transcatheter aortic valve replacement.
*All patient groups: all SAVR+TAVR. 
†For the LGE columns, 61 subjects (32 TAVR and 29 SAVR) did not undergo LGE imaging.
‡All SAVR: SAVR+SAVR/CABG.
§This variable of counts contains missing data—for example, 46 missing NYHA (incomplete data), 5 missing bicuspid aortic valve data points, 26 baseline CAD 
missing data points, and 1 missing MI data point.
‖LGE mass (percent) as the median of all patients, including those without LGE.
Table 1. Continued
Variable
All Patients*
(n=674)
+LGE
(n=341)†
−LGE
(n=272)† P Value
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Table 2. Univariate Parameters
Parameter
All Patients (n=674)
All-Cause Mortality (n=145) Cardiovascular Mortality (n=70)
HR z P Value 95% CI HR z P Value 95% CI
Baseline demographics
  Age* 1.92 7.04 <0.0001 1.60–2.31 2.24 5.75 <0.0001 1.70–2.95
  Male sex 0.77 −1.58 0.115 0.55–1.07 0.55 −2.47 0.014 0.35–0.88
  BMI 0.98 −1.40 0.161 0.94–1.01 0.97 −1.21 0.227 0.92–1.02
  Atrial fibrillation 2.33 4.202 <0.001 1.57–3.45 3.37 4.57 <0.0001 2.01–5.67
  Diabetes mellitus 1.32 1.48 0.139 0.91–1.90 1.93 2.63 0.009 1.18–3.14
  Hypertension 1.06 0.37 0.715 0.77–1.47 1.02 0.08 0.940 0.64–1.63
  Bicuspid AoV 0.28 −4.43 <0.0001 0.16–0.50 0.25 −3.23 0.001 0.11–0.58
  Previous CAD 1.69 3.02 0.003 1.20–2.38 1.98 2.77 0.006 1.22–3.20
  Previous PCI or CABG 1.51 2.09 0.037 1.03–2.24 1.82 2.17 0.030 1.06–3.11
  Previous MI 0.74 −1.17 0.244 0.44–1.23 0.67 −1.10 0.271 0.33–1.36
  Baseline NYHA functional class         
   II 2.70 2.12 0.034 1.08–6.80 2.82 1.39 0.163 0.66–12.17
   III 4.16 3.05 0.002 1.66–10.40 5.60 2.35 0.019 1.33–23.52
   IV 8.75 4.01 <0.0001 3.03–25.21 15.28 3.40 <0.001 3.17–73.67
Baseline medications
  ACE inhibitor or ARB 1.37 1.78 0.076 0.97–1.94 1.50 1.61 0.107 0.92–2.44
  β-Blocker 1.19 1.04 0.300 0.85–1.67 1.45 1.53 0.127 0.90–2.32
  Aldosterone antagonist 0.82 −0.52 0.607 0.38–1.76 1.44 0.85 0.398 0.62–3.34
  Statin 1.16 0.83 0.408 0.82–1.65 1.30 1.01 0.314 0.78–2.15
  STS score 1.18 7.78 <0.0001 1.13–1.23 1.22 7.15 <0.0001 1.15–1.28
  EuroSCORE 1.10 5.20 <0.0001 1.06–1.13 1.12 5.35 <0.0001 1.08–1.17
Echocardiography data
  Mean AoV gradient 1.00 0.84 0.402 0.99–1.02 0.99 −0.66 0.509 0.97–1.01
  Peak AoV gradient 1.00 0.83 0.407 1.00–1.01 1.00 −0.33 0.740 0.99–1.01
  AoV area 0.33 −2.30 0.021 0.13–0.85 0.23 −2.05 0.040 0.06–0.94
  AoV area indexed to BSA 0.30 −1.36 0.173 0.05–1.70 0.26 −1.03 0.301 0.02–3.32
Estimated PA pressure
  Moderate 2.10 2.73 0.006 1.23–3.58 3.07 2.86 0.004 1.42–6.63
  Severe 4.09 3.98 <0.0001 2.04–8.20 7.10 4.28 <0.0001 2.90–17.41
CMR data
  LV end-diastolic volume index 1.00 1.17 0.242 1.00–1.01 1.00 0.91 0.366 1.00–1.01
  Indexed LV stroke volume 0.97 −4.27 <0.0001 0.95–0.98 0.96 −4.11 <0.0001 0.94–0.98
  LV ejection fraction 0.98 −4.87 <0.0001 0.97–0.99 0.97 −5.06 <0.0001 0.95–0.98
  Maximal LV wall thickness 0.93 −2.45 0.014 0.88–0.99 0.91 −2.22 0.026 0.84–0.99
  Indexed LV mass 1.00 −0.29 0.769 0.99–1.01 1.00 −0.24 0.811 0.99–1.01
  RV end-diastolic volume index 1.00 −0.48 0.628 0.99–1.01 1.00 −0.15 0.878 0.98–1.01
  RV ejection fraction 0.98 −3.29 0.001 0.96–0.99 0.96 −3.68 0.002 0.95–0.98
  Indexed LA volume 1.01 3.17 0.002 1.00–1.02 1.02 3.66 <0.001 1.01–1.03
  CMR AoV regurgitant fraction 0.99 −0.82 0.412 0.98–1.01 0.98 −1.32 0.186 0.96–1.01
  Valvulo-arterial impedance 1.17 1.93 0.054 1.00–1.37 1.21 1.62 0.106 0.96- 1.51
LGE
  LGE presence/absence 2.22 4.00 <0.0001 1.50–3.28 3.38 3.92 <0.0001 1.84–6.22
(Continued )
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AS is important, because it is the most common valvu-
lar heart disease in the developed world (>3% of those 
>75 years of age), and the advent of TAVR now offers 
a treatment option for many of those with significant 
comorbidities who were previously deemed inoperable. 
Current guidelines recommend valve intervention to im-
prove survival and symptom status when AS is severe 
and ventricular decompensation is present, suggested 
by the onset of symptoms or a reduction in LV ejection 
fraction.4 We have highlighted in this study an addition-
al component of this risk-benefit analysis that has been 
underrecognized: silent irreversible scar is very common 
and is associated with increased mortality. Moreover, the 
greater the scar burden, the higher the mortality. Previ-
ous studies have suggested that operating earlier may 
be beneficial for patients, but identifying which patients 
are likely to benefit is difficult given that many will re-
main asymptomatic for years. Our findings suggest that 
scar burden might be used to optimize the timing of sur-
gical intervention, with half of patients demonstrating 
Table 3. Multivariable Model: All-Cause and Cardiovascular Mortality
 
All Patients (n=674)
HR z P Value 95% CI χ2 (P Value)
All-cause mortality (n=145)
  CMR RV ejection fraction 1.01 0.89 0.374 0.99–1.04 –862.7
  CMR LV ejection fraction 1.00 –0.15 0.879 0.98–1.02 12.5 (<0.001)
  CMR BSA-indexed LA volume 1.00 0.64 0.520 0.99–1.02 140.4 (<0.0001)
  Atrial fibrillation 1.39 0.87 0.383 0.66–2.92 7.3 (0.007)
  LV maximal wall thickness 0.93 –1.85 0.064 0.85–1.01 4.6 (0.032)
  STS score 1.12 2.68 0.007 1.03–1.22 38.8 (<0.0001)
  CMR BSA-indexed LV SV 1.00 –0.21 0.832 0.97–1.02 3.9 (0.050)
  CAD 0.99 –0.05 0.963 0.59–1.65 11.3 (<0.001)
  AVA (by echocardiography) 1.10 0.18 0.855 0.39–3.12 571.6 (<0.0001)
  Age* 1.50 2.61 0.009 1.11–2.04 5.0 (0.026)
  LGE presence 2.39 3.22 0.001 1.40–4.05 129.7 (<0.0001)
  Bicuspid aortic valve 0.67 –1.01 0.315 0.31–1.46 1.95 (0.163)
Cardiovascular-only mortality (n=70)
  Female sex 2.17 –2.89 0.004 1.28–3.70 −89.4 
  Previous CAD 1.53 1.60 0.110 0.91–2.56 28.0 (<0.0001)
  CMR LV EF 0.98 –2.50 0.013 0.97–1.00 22.8 (<0.0001)
  Atrial fibrillation 1.43 1.17 0.240 0.79–2.58 8.2 (0.004)
  Age* 1.94 4.41 <0.0001 1.44–2.60 21.3 (<0.0001)
  LGE presence 3.14 3.47 <0.001 1.65–5.99 82.2 (<0.0001)
AVA indicates aortic valve area; BSA, body surface area; CAD, coronary artery disease; CMR, cardiac magnetic resonance; EF, ejection 
fraction; HR, hazard ratio; LA, left atrial; LGE, late gadolinium enhancement; LV, left ventricular; RV, right ventricular; STS, Society of Thoracic 
Surgeons; and SV, stroke volume.
*Using age variable scaled by epochs of 10.
  LGE pattern         
   Noninfarct 2.08 3.40 <0.001 1.36–3.17 2.80 3.06 0.002 1.45–5.40
   Infarct 2.49 3.79 <0.001 1.55–4.00 4.54 4.36 <0.0001 2.30–8.97
  LGE mass, per 1% increase 1.07 4.00 <0.0001 1.04–1.11 1.09 3.78 <0.001 1.04–1.13
ACE indicates angiotensin-converting enzyme; AoV, aortic valve; ARB, angiotensin receptor blocker; BMI, body mass index; BSA, body surface area; CABG, 
coronary artery bypass grafting; CAD, coronary artery disease; CMR, cardiac magnetic resonance; HR, hazard ratio; LA, left atrial; LGE, late gadolinium enhancement; 
LV, left ventricular; MI, myocardial infarction; NYHA, New York Heart Association; PA, pulmonary artery; PCI, percutaneous coronary intervention; RV, right ventricular; 
and STS, Society of Thoracic Surgeons.
*Using age variable scaled by epochs of 10.
Table 2. Continued
Parameter
All Patients (n=674)
All-Cause Mortality (n=145) Cardiovascular Mortality (n=70)
HR z P Value 95% CI HR z P Value 95% CI
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Figure 2. All-cause and cardiovascular mortality in severe aortic stenosis by late gadolinium enhancement (LGE) status. 
Kaplan-Meier (KM) survival plots showing all-cause (left) and cardiovascular (CV; right) mortality in all patients (A and B; n=674), patients treated with surgical aor-
tic valve replacement (SAVR; C and D; n=399), and patients treated with transcatheter aortic valve replacement (TAVR; E and F; n=275), according to the presence 
or absence of LGE preoperatively. TAVI indicates transcatheter aortic valve implantation.
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irreversible scar and a consequent doubling of postop-
erative medium-term mortality. Noninfarct pattern scar 
was twice as prevalent as infarct scar, and both predict-
ed worse outcome, as previously suggested.8,9 In asymp-
tomatic severe AS, the risks of early surgery (1%–2% 
mortality) and prolonged risk of prosthesis-associated 
complications (eg, endocarditis, pacemaker dependen-
cy, bleeding, thrombosis, valve degeneration) need to 
be balanced against the “silent” risk of sudden cardiac 
death (1.5%/y) and increased risk of intervention and 
long-term outcome after symptoms have developed.21 
Our results may therefore provide a mechanism for bet-
ter selection of appropriate patients for early surgery, 
but this remains to be tested.
Potential Pathophysiology of Scar 
Formation
The ventricle in AS initially responds to pressure load-
ing by LV hypertrophy resulting in adaptive LV remod-
eling to maintain wall stress and cardiac performance. 
Despite compensatory capillary vasodilatation, over 
time, myocardial oxygen demand outstrips supply, 
leading to subendocardial ischemia and eventually LV 
decompensation.22–24 The transition to LV decompen-
sation occurs by fibrosis and myocyte degeneration 
with irreversible cell loss, mainly by autophagy and 
oncosis.6 This process is driven by subendocardial isch-
emia and preceded by 2 phenomena: perfusion de-
fects and troponin elevation (indicating myocardial cell 
death).25,26 Replacement fibrosis ensues, which starts 
in the subendocardial layers first, then over time af-
fects deeper myocardial layers,17 and in turn contrib-
utes significantly to the progression of LV systolic dys-
function.6 Diffuse myocardial fibrosis, with increased 
collagen I and III deposition around cardiomyocytes 
and bundles, occurs predominantly in the midmyocar-
dium.17 Patchy foci of fibrosis on LGE imaging can be 
indicative of widespread diffuse fibrosis. Diffuse fibro-
sis can be assessed by CMR T1 mapping
17,27 but was 
Figure 3.  All-cause mortality in severe aortic stenosis (AS) by late gadolinium enhancement (LGE) pattern. 
Kaplan-Meier (KM) survival plot showing all-cause mortality in all patients with severe AS (n=674) by pattern of late gadolinium enhancement (no LGE, infarct LGE, 
noninfarct LGE; both P<0.001). The plot summarizes 6-year follow-up data.
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not investigated in this study because it has become 
available only more recently.
Focal fibrosis identified by LGE is associated with ad-
verse outcome across a wide range of myocardial pa-
thologies28 and has been shown in small single-center 
studies to be associated with outcome in AS.7–10 The 
presented data place LGE-detected scar firmly as a key 
outcome predictor in AS and suggest that current tim-
ing of valve intervention (TAVR or SAVR), based on a 
combination of valve severity and symptoms, may be 
too late for optimal long-term outcomes. This was 
highlighted in a recently completed multicenter obser-
vational study in asymptomatic patients with moderate 
to severe AS (the PRIMID-AS study [Microvascular Dys-
function in Aortic Stenosis]; NCT01658345) showing 
that the presence of scar on LGE did not predict symp-
tom onset.14
Earlier intervention, for example, in asymptomatic 
severe AS, may therefore warrant investigation. Despite 
numerous observational studies to assess risk prediction 
in asymptomatic AS, there have been no randomized 
trials of early intervention to improve outcome. Patients 
at risk of myocardial decompensation resulting from scar 
or myocardium in the process of developing scar can 
be identified early through the use of high-sensitivity 
troponin, perfusion defects, or CMR LGE techniques.15 
One study that will go some way in addressing this is-
sue is the EVOLVED-AS trial (Early Valve Replacement 
Guided by Biomarkers of LV Decompensation in As-
ymptomatic Patients With Severe AS; NCT03094143), 
a parallel-group, multicenter, prospective randomized 
(open-label blinded end point) trial of early aortic valve 
intervention in asymptomatic patients with severe AS 
and evidence of LV decompensation, as evidenced by 
noninfarct pattern LGE. In the absence of prospective 
randomized trials, only registry data suggest the likely 
impact of early surgery.29,30
Stratifying intervention on the basis of the presence 
of LGE may be too late because even the small amount 
of scar detected in our cohort is associated with resid-
ual increased risk of all-cause and cardiovascular mor-
tality, but until EVOLVED-AS and further studies report 
results, the role of, timing of, and intervals for CMR 
to guide decision making in patients with moderate to 
severe AS remain unclear.
Our study has limitations. This was an observational 
study of patients at surgical centers with an interest in 
CMR and echocardiography for clinical and research 
indications, potentially introducing selection bias. As a 
result of the contraindications for contrast-enhanced 
CMR, patients with severe renal impairment and pre-
operative pacemaker/defibrillators were not represent-
ed. Sixty-one patients did not undergo LGE imaging. 
There were no reported invasive measures of hemody-
namics (during angiography), hematocrit, brain natri-
uretic peptides, or blood troponin; per clinical routine, 
renal function was checked before LGE CMR but was 
not systematically captured or easily retrieved for this 
analysis. Furthermore, no routine imaging follow-up 
was performed. Although studies of other populations 
have shown that unrecognized infarct scar increases 
with age31 and can be found in up to 10% of sub-
jects, this would account for only a minority of the 
scar burden found in our population. Both TAVR and 
SAVR have been associated with de novo LGE, which 
may be associated with further myocardial decompen-
sation.32,33 Because of the lack of follow-up CMR data, 
the possibility of further periprocedural damage could 
not be excluded. Finally, multivariate analysis was not 
controlled for the type of intervention. This may have 
been important in TAVR in particular, for which the 
learning curve and patient selection have changed 
over the years.
CONCLUSIONS
In patients with severe AS, preoperative focal myocar-
dial scar is independently associated with mortality, its 
presence being associated with a 2-fold higher late 
mortality.
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